CTI BioPharma Corp. (NASDAQ: CTIC) is 133.47% higher on its value in year-to-date trading and has touched a low of $1.43 and a high of $7.80 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CTIC stock was last observed hovering at around $5.36 in the last trading session, with the day’s gains setting it 0.43%.
Currently trading at $5.79, the stock is -6.55% and -7.46% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.1 million and changing 8.02% at the moment leaves the stock 28.38% off its SMA200. CTIC registered 89.84% gain for a year compared to 6-month gain of 33.72%. The firm has a 50-day simple moving average (SMA 50) of $42.10 and a 200-day simple moving average (SMA200) of -$5.52.
The stock witnessed a -7.06% loss in the last 1 month and extending the period to 3 months gives it a -2.85%, and is -6.46% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.83% over the week and 6.51% over the month.
CTI BioPharma Corp. (CTIC) has around 121 employees, a market worth around $703.14M and $14.60M in sales. Fwd P/E is 120.62. Distance from 52-week low is 304.90% and -25.77% from its 52-week high.
CTI BioPharma Corp. (CTIC) Analyst Forecasts
CTI BioPharma Corp. is expected to release its quarterly report on 11/14/2022.The EPS is expected to shrink by -47.40% this year
CTI BioPharma Corp. (CTIC) Top Institutional Holders
The shares outstanding are 114.39M, and float is at 114.17M with Short Float at 13.81%.
CTI BioPharma Corp. (CTIC) Insider Activity
A total of 31 insider transactions have happened at CTI BioPharma Corp. (CTIC) in the last six months, with sales accounting for 19 and purchases happening 12 times. The most recent transaction is an insider sale by KIRSKE DAVID, the company’s EVP, Chief Financial Officer. SEC filings show that KIRSKE DAVID sold 22,592 shares of the company’s common stock on Sep 16 at a price of $6.02 per share for a total of $0.14 million. Following the sale, the insider now owns 16913.0 shares.
CTI BioPharma Corp. disclosed in a document filed with the SEC on Sep 12 that Craig Adam R (President and CEO) sold a total of 242,300 shares of the company’s common stock. The trade occurred on Sep 12 and was made at $6.43 per share for $1.56 million. Following the transaction, the insider now directly holds 27861.0 shares of the CTIC stock.
Still, SEC filings show that on Aug 16, Craig Adam R (President and CEO) acquired 5,000 shares at an average price of $5.50 for $27500.0. The insider now directly holds 27,861 shares of CTI BioPharma Corp. (CTIC).
CTI BioPharma Corp. (CTIC): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 36.17% up over the past 12 months and Madrigal Pharmaceuticals Inc. (MDGL) that is -20.55% lower over the same period. Bristol-Myers Squibb Company (BMY) is 18.52% up on the 1-year trading charts.